Increased plasma conc w/ CYP3A4 inhibitors eg, clarithromycin, itraconazole, ritonavir; P-gp & BCRP efflux transporters eg, cyclosporine, verapamil, quinidine. Increased exposure w/ moderate CYP3A4 inhibitors eg, diltiazem, erythromycin, fluconazole. Decreased plasma conc w/ strong (eg, phenobarb, rifampicin, St. John's wort) or moderate (eg, bosentan, efavirenz, modafinil) CYP3A4 inducers.